Key points are not available for this paper at this time.
We have developed and externally validated a prediction model for response to methotrexate within 24 weeks in DMARD-naïve patients with RA, providing variably weighted clinical features and defined cutoffs for clinical decision-making.
Duong et al. (Fri,) studied this question.